Source: Eur Respir J 2011; 37: 1158-1165
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Leber A., Marras T.K.. The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada. Eur Respir J 2011; 37: 1158-1165

Member's Comments

No comment yet.

Related content which might interest you: The impact of new ATS/IDSA guideline for nontuberculous mycobacterial disease on the diagnosis of nontuberculous mycobacterial lung disease in Korea Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Source: Virtual Congress 2020 – German programme 2020 Year: 2020 Pulmonary diseases due to non-tuberculous mycobacteria in TB referral clinical center Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 New international (ATS/ERS/ESCMID/IDSA) guidelines for the management of NTM pulmonary diseases Source: ERS Webinar 2020: New international (ATS/ERS/ESCMID/IDSA) guidelines for the management of NTM pulmonary diseases Year: 2020 Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response Source: Eur Respir J 2004; 23: 741-746 Year: 2004 Comparison of treatment practices for nontuberculous mycobacterial pulmonary disease in Japan, Europe, and United States Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Pathogenicity of NTM: new developments Source: Annual Congress 2007 - Nontuberculous mycobacteria (NTM): a slow-growing challenge Year: 2007 Active case-finding of tuberculosis in Europe Source: Annual Congress 2007 - Clinical epidemiology of tuberculosis Year: 2007 Prevalence of non-tuberculous mycobacterial disease among patients evaluated for pulmonary tuberculosis in Iraq 2015-2018 Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019 The non-tuberculous pulmonary disease experience in a general respiratory clinic in the UK Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021 The prevalence of non-tuberculous mycobacterium pulmonary infection in a tertiary hospital in Singapore Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Actual treatment practices of pulmonary nontuberculous mycobacteriosis analysed from national insurance claim data in Japan Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM) Year: 2018 The increasing trend of nontuberculous mycobacterial pulmonary diseases in a tertiary referral hospital in South Korea between 2006 and 2016 Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019 The prevalence and clinical profile of non-tuberculous mycobacterial pulmonary infection in Singapore Source: International Congress 2018 – Respiratory epidemiology:  from infectious diseases to lung cancer Year: 2018 Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Source: Guideline 2020 Year: 2020 Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Source: Eur Respir J, 56 (1) 2000535; 10.1183/13993003.00535-2020 Year: 2020 Nontuberculous mycobacterial disease within UK primary care, 2006-2016 Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018 Beyond pulmonary nontuberculous mycobacteria disease: do extra-pulmonary forms represent an emerging clinical and public health threat? Source: ERJ Open Res, 3 (3) 00091-2017; 10.1183/23120541.00091-2017 Year: 2017